Упрощенная HTML-версия
115
nese-American men / R.W. Bergstrom, L.I. Newel-Morris, D.L. Leonetti et al. //
Diabetes. – 1990. – V. 39. – P. 104-111.
62.
Blair D. Evidence for an increased risk for hypertention with central-
ly located body fat and the effect of race and sex on this risk / D. Blair, J.P. Ha-
bricht, S. Abraham et al. // Am J Epidemiol. – 1984. – V.119. – P.526-540.
63.
Blann A.D. Hypothesis: Is soluble P-selectin a new marker of plate-
let activation in essential hypertension? / A.D. Blann, G.Y.H. Lip // J. Cardiovasc.
– 1984. – V. 6. – P. 840-843.
64.
Blann A.D. Von Willebrand factor and endothelial damage in essen-
tial hypertension / A.D. Blann, T. Naqvi, M. Waite, C.N. McCollum // J Hum
Hypertens. – 1993. – V. 7. – P. 107–111.
65.
Blann A.D. Soluble P-selectine in atherosclerosis; a comparison with
endothelium cells and platelet marcers / A.D. Blann, G.Y.N. Lip, D.G. Beevers et
al. // Thromb. Haemost. – 1997. – V. 77. - № 6. – P. 1077-1080.
66.
Bo Isoma. Cardiovascular Morbidity and Mortality associated with
the metabolic syndrome / Bo Isoma, P. Almgren, T. Tuomi et al. // Diabet Care. –
2001. – V. 24. – P. 683-689.
67.
Bonora E. Prevalence of insulin resistence in metabolic disorders:
the Bruneck Study / E. Bonora, S. Kiechl, J. Willeit, et al. // Diabetes. – 1998. –
V. 47. – P. 1643-1649.
68.
Bruning T.A. In vivo characterization of muscarinic receptor sub-
types that mediate vasodilation in patients with essential hypertention / T.A.
Bruning, P.S. Chang, G.C. Hendriks et al. // Hypertension. – 1995. – V.26. –
P.70-77.
69.
Calver A. Effect of local intra-arterial NG-monomethyl- L-arginine
in patients with hypertension: the nitric oxide dilator mechanism appears abnor-
mal / A. Calver, J. Collier, S. Moncada et al. // J Hypertens. – 1992. – V. 10. – P.
1025-1031.